Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01073228 · ClinicalTrials.gov registry record · Phase 2
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 409
- Enrollment target
NCT01073228 is a Phase 2 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 409 participants.
The verdict
NCT01073228, a Phase 2 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 409 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01073228
The ClinicalTrials.gov registry entry for NCT01073228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01073228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01073228 about?
NCT01073228 is a clinical study titled "Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease". This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
What is the current status of trial NCT01073228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2010-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01073228?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01073228?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.